Clinical utilities of aromatase inhibitors in breast cancer

Figures & data

Table 1 Classification of AIs

Generations	Type 1 steroidal inhibitors	Type 2 non-steroidal inhibitors
Nonspecific inhibitor		Aminoglutethimide
Previous selective inhibitors not currently in clinical use	Formestane	Fadrozole Rogletimide Vorozole
Selective oral inhibitors currently in clinical use	Exemestane (Aromasin^®)	Anastrozole (Arimidex^®) Letrozole (Femara^®)

Note: Reprinted from The Journal of Steroid Biochemistry and Molecular Biology, Vol 125, Saranya Chumsri, Timothy Howes, Ting Bao, Gauri Sabnis, and Angela Brodie, Aromatase, aromatase inhibitors and Molecular Biology, pages 13–22., Copyright (2011), with permission from Elsevier.⁶

Abbreviation: AIs, aromatase inhibitors.

ChumsriSHowesTBaoTSabnisGBrodieAAromatase, aromatase inhibitors, and breast cancerJ Steroid Biochem Mol Biol20111251–2132221335088

 PubMed Web of Science ®Google Scholar